Kawasaki, Gunma, Japan, Feb 25, 2026 - (JCN Newswire via SeaPRwire.com) - BEISIA CO., LTD. and Fujitsu Limited today announced that both companies have begun introducing and operating Fujitsu's Advanced Operation & Management offering for digitalizing stores and improving labor productivity at Beisia stores. This solution, part of Fujitsu’s Uvance business model, is being used to automate the temperature management of refrigerator and freezer facilities within stores. The companies plan to implement the solution in all 138 Beisia stores across Japan by May 2026.Introduction of the solution commenced in December 2025This initiative will streamline operations for store employees in complying with HACCP requirements(1), enhancing product freshness management and reducing food loss by providing alert notifications when abnormalities exceeding set thresholds are detected.Under its Uvance business model, which addresses societal challenges, Fujitsu will leverage the knowledge and experience gained from implementing Advanced Operation & Management at Beisia to drive the digitalization of stores through data and AI, enhance labor productivity and promote sustainable store operations.OverviewPrior to the full-scale rollout, Beisia conducted a practical verification of the solution at its Beisia Foods Park Takasaki Kuragano store (Takasaki City, Gunma Prefecture). After confirming the effectiveness of temperature data acquisition and management, as well as the efficiency gains for employees, Beisia decided to implement the solution across all its stores, with sequential deployment beginning in December 2025.Fujitsu's Advanced Operation & Management is a solution that visualizes data acquired from various IoT sensors in real-time. A key feature is its rapid deployment and operation through the attachment of IoT sensors to existing equipment, without dependency on specific hardware.At Beisia, IoT sensors attached to refrigeration and freezing equipment throughout the stores will extract and visualize temperature information in real-time. This eliminates the need for manual inspection and recording by store employees, significantly reducing their workload.Moreover, when abnormalities exceeding thresholds or conditions are detected, alerts are promptly sent to the store's operational communication tools. This enables quicker initial responses to anomalies, strengthening product freshness management, and reducing food loss. Additionally, both headquarters and individual stores can access the same real-time information via a dashboard, facilitating centralized management of information from multiple stores and supporting overall store operation optimization.In Japan, the revised Food Sanitation Act(2) mandates the implementation of HACCP, an international standard for food hygiene management, for all food-related businesses. In the supermarket retail industry, thorough temperature management is crucial for product freshness and consumer trust. However, with a severe labor shortage, streamlining inspection and recording tasks has become an urgent issue.Previously, Beisia stores manually recorded temperatures twice a day for an average of 150 refrigeration and freezing units per store, posing a significant workload for employees. Against this backdrop, Beisia decided to introduce a solution to automate temperature management for its in-store refrigeration and freezing equipment.Figure 1: Overview of Fujitsu's IoT Visualization SolutionFigure 2: IoT Sensor installed in a Beisia store freezer(1) HACCP (Hazard Analysis and Critical Control Point):A food hygiene management method that ensures product safety by identifying and managing critical control points throughout the entire food production process, from raw material reception to product shipment, to eliminate or reduce hazards such as food poisoning bacteria contamination and foreign object mixing.(2) Revised Food Sanitation Act:A law designed to ensure food safety in response to changes in the food environment and globalization. Revised in 2018, it mandated HACCP implementation.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
国泰君安国际获批使用SIMM 衍生品风险管理接轨国际标准
香港, 2026年2月25日 - (亚太商讯 via SeaPRwire.com) - 2月23日，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK））宣布，已正式获得香港证券及期货事务监察委员会（SFC）批准，自2026年2月12日起可在其两家持牌机构（国泰君安证券（香港）有限公司及国泰君安外汇有限公司）采用国际掉期与衍生工具协会ISDA标准初始保证金模型（Standard Initial Margin Model, "SIMM" ）计算场外衍生品交易的初始保证金。ISDA SIMM 是业界通用的标准方法论，专门用于计算非集中清算衍生品的监管初始保证金。该模型通过建立统一的计算标准，使所有市场参与者得以遵循同一框架进行保证金核算，不仅避免了各机构独立开发模型所产生的额外成本，还有效减少了因算法差异引发的潜在争议。其配套的治理框架进一步确立了行业共同实践，确保保证金计提既符合全球监管要求，又充分保障了保证金的充足性。此次获批标志着国泰君安国际场外衍生品业务的风险管理能力迈上新台阶，在巩固合规与风控标杆的同时，显著提升中资券商国际化竞争力。通过采用国际市场通行的SIMM模型，公司得以接轨国际大行标准，能够更精准、高效地管理初始保证金，在有效控制交易对手风险的同时，显著节省交易成本，实现更高资本效率，增强与全球机构对手方的合作信任，从而提升业务的长期竞争力。此次获批不仅是对公司衍生品业务技术实力的认可，更是监管机构对公司内部控制、尤其是风险管理能力的又一里程碑式肯定。展望未来，国泰君安国际将进一步精进衍生品业务的内控管理体系，筑牢长远稳定发展的根基。同时，作为香港资本市场的重要一员，公司将一如既往地配合监管机构，深度参与市场基础设施建设，助力提升香港场外衍生工具市场的国际竞争力与活力。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"A"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球81%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication. Impressive phase III trial data in AD Its Priority Review is expected to accelerate its NDA approval Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas. Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated. Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date. Building an integrated AD solution, strengthening Dermavon’s leadership in dermatology AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care. Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3]. The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/
Hong Kong Tech Delegation Heading for Market Expansion at Mobile World Congress 2026
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – Hong Kong Trade Development Council (HKTDC), in collaboration with Hong Kong Science and Technology Parks Corporation (HKSTP), will lead a delegation of 21 Hong Kong tech companies and institutions to showcase at Mobile World Congress (MWC) 2026—the world’s premier connectivity event, and debut at 4 Years From Now (4YFN) 2026—a global stage for start-ups, taking place concurrently 2-5 March in Barcelona, Spain. Building on the momentum from MWC 2025, the Delegation will be featuring solutions beyond the Connectivity category, covering focus areas across Devices and Systems, Digital Transformation and support from Ecosystem Partners. The Pavilion duet ought to give a more comprehensive picture of Hong Kong’s innovation and technology (I&T) capabilities in engaging global telecom leaders, enterprise decision-makers, industry partners, and investors, bridging cutting-edge research and development (R&D) into real-world applications and propelling Hong Kong’s I&T sector onto the international stage.Iris Wong, Director, Merchandise Trade and Innovation / Director, External Relations, HKTDC, said, “The Hong Kong Tech Pavilion is an ideal platform for Hong Kong tech enterprises to present their latest R&D achievements at major international tech gatherings, support their journey to explore overseas markets, while highlighting Hong Kong’s strengths as an international innovation and technology hub.”Derek Chim, Head of Startup Ecosystem and Development, HKSTP said, “MWC is a global bellwether for communications technology and tech companies at any stage, to connect with the industry and investors, to have a solid ground that validate solutions, catalyse pilot projects, accelerate commercialisation, and scale internationally.”A series of dialogues and exchanges, spanning from networking reception and themed talks to pitching sessions, will take place throughout the events at the Pavilion to facilitate partnerships and investment opportunities for innovative solutions that are market-ready with high potential for market expansion, in particular, Asmote and Cresento under “Connectivity” make stellar examples of the notion:5G & 6G for Communication, Sensing, and AI computing – Shannon & Turing, (Asmote), located at MWC, specialises in mmWave technology for Integrated Sensing and Communication (ISAC) technology—drone communications and control—rising to the occasion as the city advances its low-altitude economy initiatives, while winning favors for its efficiency in managing industrial scenarios such as smart ports and dark factories. The company previously secured the world’s first 26GHz mmWave 5G commercial communications project, demonstrating its leadership in industrial-grade applications.Smart Performance Insights for Sport – Cresento, located at 4YFN, focused on developing an AI-powered shin guard to deliver real-time insights—performance analytics, team leaderboards, and more—with a design that incorporates into gears that athletes already wear and creates minimal friction for, in particular, football players to adapt, will be moving from prototypes to pilot collaborations with European football clubs, academies and sport tech platforms and distributors.HKTDC continues to join hands with HKSTP to support Hong Kong tech enterprises to “go global” by jointly organising the Hong Kong Tech Pavilion to build bridges linking tech companies with the world. This expedites the industry’s progress in internationalisation to meet the growing demand for I&T globally. This will attract talents, facilitate forward-looking investments and explore opportunities globally, realising the mission of entrepreneurs to reach out to the world and further consolidate Hong Kong’s position as an international I&T hub.Mobile World Congress Barcelona (MWC) & 4 Years From Now (4YFN)Date: 2-5 March 2026Venue: Fira Gran Via, Av. Joan Carles I, 64, 08908 L'Hospitalet de Llobregat, Barcelona, SpainHong Kong Tech Pavilion:MWC – Booth 6E44 at Hall 64YFN – Booth 8.1B31 at Hall 8.1Please visit https://bit.ly/MWC2026HKTech for more information on Hong Kong Tech Pavilion and the exhibitors.Full list of 21 tech entities showcasing at Hong Kong Tech Pavilion during MWC and 4YFN 2026 (in alphabetical order):MWC 2026 - Booth 6E44 at Hall 61 Entoptica Limited Devices & Systems2 eSIX Connectivity3 Faraconix Technologies Co., Ltd. Connectivity4 FreightAmigo Services Limited Digital Transformation5 Glassdio Scientific Company Limited Connectivity6 Harvest Elite International Limited Digital Transformation7 HongKong Umedia Limited Devices & Systems8 iASPEC Services Limited Digital Transformation9 InvestHK Ecosystem Partners10 Robocore Technology Limited Devices & Systems11 Shannon & Turing Technology Limited Connectivity12 The Hong Kong Polytechnic University Ecosystem Partners13 Xeroptix Technology Devices & Systems4YFN 2026 - Booth 8.1B31 at Hall 8.114 AIGM Limited Digital Transformation15 BWSea Technology (HK) Co., Limited Digital Transformation16 Cresento Limited Devices & Systems17 GoGoChart Technology Limited Digital Transformation18 HairCoSys Limited Devices & Systems19 KNQ Technology Limited Digital Transformation20 Solos Technology Limited Devices & Systems21 Vista Innotech Limited Devices & SystemsAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 16,000 research professionals and around 2,600 technology companies from 24 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.More information about HKSTP is available at www.hkstp.org.Media Contact: Hong Kong Science and Technology Parks CorporationHong Kong Trade Development CouncilAngela LauTel: +852 6535 7611Email: angela.lau@hkstp.orgWinnie KanTel: +852 2584 4055Email: winnie.wy.kan@hktdc.org Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
SHENZHEN, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product's review process for marketing approval in the AD indication.Impressive phase III trial data in ADIts Priority Review is expected to accelerate its NDA approvalRuxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product's expansion into multiple therapeutic areas.Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.Building an integrated AD solution,strengthening Dermavon’s leadership in dermatologyAD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
TOKYO, Feb 24, 2026 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd. (Head office: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) will provide and donate gold, silver, and bronze medals to the top three men and women finishers of the marathon and wheelchair marathon events at the Tokyo Marathon 2026. The Tokyo Marathon 2026 is organized by the Tokyo Marathon Foundation and will be held on March 1, 2026.Design Representing All the Participants in the Event with Woven LinesThe medals were designed based on the concept of the Tokyo Marathon: The Day We Unite. On the front of the medal, the logo type is placed horizontally above the event logo pattern, which represents “runners, supporters, and cheerers,” to express the image of the Tokyo Marathon, which is held based on the involvement of many people, including runners, as well as volunteer staff and cheerers.On the back of the medal, the name of the event, Tokyo Marathon 2026, is written in Braille, and the words “FINISHER” and the event date are engraved, along with TANAKA’s logo. The medal’s ribbon design continues the 2016 design and is based on the event logo, which resembles a tapestry of lines woven together to represent all the runners, volunteers, and spectators.Sustainability InitiativesThe Tokyo Marathon 2026 is advancing sustainability initiatives centered on “waste reduction,” “environmental conservation,” and “DEI (Diversity, Equity & Inclusion).” In support of this initiative, the medal ribbons are made using recycled polyester. In addition, for the gold medals, the gold plating solution used is from TANAKA’s “RE Series” regenerated precious metals made using only 100% recycled materials. Through these initiatives, TANAKA is helping to make the event more sustainable.About the Tokyo Marathon 2026The Tokyo Marathon 2026 is the 19th edition of one of the largest public participation marathons in Japan. As it will celebrate its 20th anniversary in 2027, the event has evolved further to help all the participants play active roles so that the metropolis of Tokyo unite as one, based on three pillars: “The safest and most secure race in the world,” “The most exciting race in the world,” and “The warmest and most friendly race in the world.” This year, the event has adopted “Run. Tokyo. Own.” as the keyword to express how, on the grand stage of Tokyo, each runner lives their own run and their own story—and how countless individuals coming together create “one Tokyo” for that day and that moment alone.TANAKA has produced the winner and finisher medals for every Tokyo Marathon since the first held in 2007, with this year marking the 19th year. The Tokyo Marathon joined the World Marathon Majors (currently the Abbott World Marathon Majors) in 2013, attracting global attention as one of the world’s seven premier marathons. Other than the Tokyo Marathon, TANAKA has also produced medals for the winners of the Tokyo Legacy Half Marathon, supported the promotion of para sports as an official partner of the Japanese Para Sports Association (JPSA), and produced and sold official commemorative medals for the 1964 Tokyo Olympic Games. As part of its contribution to the realization of an inclusive society and the creation of a healthier society, TANAKA will continue to support the promotion of sports going forward.Overview of the Tokyo Marathon 2026 MedalsWeight, size and materialGold Medal: approx. 100g 65mm in diameter and approx. 3mm: pure silver with gold platingSilver Medal: approx. 100g 65mm in diameter and approx. 3mm: pure silverBronze Medal: approx. 85g 65mm in diameter and approx. 3mm: pure copper platingRace Information of the Tokyo Marathon 2026OrganizerTokyo Marathon FoundationCo-organizersJAAF (Japan Association of Athletics Federations); Tokyo Metropolitan Government;The Yomiuri Shimbun; Nippon Television Network Corporation; Sankei Shimbun Co., Ltd.; The Tokyo Shimbun.Managing OrganizationTokyo Athletics AssociationOperation SupporterTokyo Sports Association for the Disabled; Kanto Para Athletics.Supporting OrganizationsJAPAN SPORTS AGENCY; Ministry of Land, Infrastructure, Transport and Tourism; Japan Tourism Agency; Metropolitan Tokyo Mayors' Council; Japan Sports Association; Japanese Olympic Committee; Japanese Para Sports Association;Japan Para Athletics; Nippon Keidanren (Japan Business Federation);KEIZAI DOYUKAI (Japan Association of Corporate Executives);The Tokyo Chamber of Commerce and Industry; Tokyo Medical Association;Tokyo Disaster Prevention & Emergency Medical Service Association;Tokyo Private Ambulance Call Center Registered Companies Liaison Council;TOKYO NURSING ASSOCIATION; Tokyo Convention & Visitors Bureau;Tokyo Federation of Neighborhood Associations;Tokyo Federation of Shopping Center Promotion Associations & Tokyo Federation of Shopping Centers; Tokyo Sports Association; Community Sport Leaders Tokyo; Metropolitan Expressway Co., Ltd; The Hochi Shimbun; Radio Nippon Co., Ltd.;Sankei Sports; Nippon Broadcasting System, Inc.; The Tokyo Chunichi Sports.Presenting PartnerTokyo Metro Co., Ltd.Official PartnersSTARTS CORPORATION INC.; Mastercard; OujiSeiyaku Co., Ltd.;ASICS Japan Corp.; Otsuka Pharmaceutical Co., Ltd.;KINTETSU INTERNATIONAL; SEIKO GROUP CORPORATION;The Dai-ichi Life Insurance Company, Limited; McDonald's Company (Japan), Ltd.; Mizuho Bank, Ltd.; Kokumin Kyosai co-op (National Federation of Workers and Consumers Kyosai Cooperatives); Hisamitsu Pharmaceutical Co., Inc.;Kao Corporation; Earth Corporation; Porsche Japan K.K.; realbuzz; VENEX Co., Ltd.; NIHON KOHDEN CORPORATION; KOYOU RENTIA Co., Ltd.; Fanplus, Inc.;Shimizu Octo, Inc.; SAGAWA EXPRESS CO., LTD.;TANAKA PRECIOUS METAL GROUP Co., Ltd.; Rokko Butter, Co., Ltd.;Hibino Corporation; Photocreate Co., Ltd; ASUENE Inc.;DateSunday, March 1, 2026*The race information is current as of the time this press release was published. For the latest information, please check the Tokyo Marathon official website.About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ended December 2024 were 846.9 billion yen.TANAKA PRECIOUS METAL GROUP Co., Ltd.TANAKA Corporate Websitehttps://www.tanaka.co.jp/english/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.co.jp/support/req/other_contact_e/index.htmlPress Release: https://www.acnnewswire.com/docs/files/20260224_EN.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
康哲药业（867.HK/8A8.SG）：创新药磷酸芦可替尼乳膏增加特应性皮炎（AD）适应症中国上市许可申请获受理并获纳入优先审评
深圳, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司 （"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业日期为2025年4月22日发布的公告）已于2026年2月24日获得中国国家药品监督管理局（NMPA）受理磷酸芦可替尼乳膏（"产品"）轻中度特应性皮炎（"AD"）的新药上市许可申请（NDA）。产品拟用于其他外用药控制不佳或不建议使用时，非免疫功能受损的2岁及以上儿童和成人轻中度特应性皮炎的局部短期和非持续性慢性治疗。且该项NDA因"符合儿童生理特征的儿童用药品新品种、剂型和规格"，已获得NMPA药品审评中心批准纳入优先审评品种名单，有望加快产品AD适应症上市审评进程。特应性皮炎III期临床数据亮眼，优先审评加速上市磷酸芦可替尼乳膏已于2026年1月获得NMPA批准上市，成为中国批准的首款且唯一用于白癜风治疗的靶向药。此次增加AD适应症NDA获受理，是产品向多治疗领域拓展的关键里程碑。磷酸芦可替尼乳膏已在轻中度AD的一项随机、双盲、安慰剂对照中国三期药物临床研究取得积极结果：- 疗效优异：产品成功达到主要终点，即使用产品治疗8周，达到研究者整体评估（IGA）评分为0或1分，且较基线改善≥2分的受试者比例，显著高于安慰剂（63.0% vs 9.2%，P<0.001）。关键次要终点，磷酸芦可替尼乳膏治疗8周，达到湿疹面积及严重程度指数评分较基线至少改善75%（EASI 75）的受试者比例亦显著优于安慰剂（78.0% vs 15.4%，P<0.001）。- 安全性良好：治疗期出现的不良事件（TEAE）的严重程度大多数为轻度或中度，未发生导致研究药物用药终止的TEAE，整体安全耐受性良好。此外，该项NDA已获批纳入优先审评品种名单。根据NMPA相关规定，适用优先审评审批程序的上市注册申请的审评时限由常规程序的200日大幅缩短为130日，审评时限将得到显著缩短，这将有望加速磷酸芦可替尼乳膏AD适应症的上市进程，早日惠及广大患者。构建特应性皮炎综合方案，强化皮肤领域竞争实力AD是一种慢性、复发性、炎症性的皮肤疾病，临床主要表现为皮肤干燥、慢性湿疹样皮损和明显瘙痒，可能严重影响患者的生活质量。据估算，2024年中国特应性皮炎患者超过5,400万人，基于SCORAD评分，轻中度特应性皮炎的占比为98%，即超过5,250万患者[1]。外用药物是AD最基本的治疗方法。传统外用药物如外用糖皮质激素（TCS）及外用钙调神经磷酸酶抑制剂（TCIs）有长期用药的不良反应或疗效有限的临床痛点，临床亟需新的治疗选择。德镁医药已针对AD构建了全方位的"治疗+护理"综合解决方案，除局部外用制剂-磷酸芦可替尼乳膏（轻中度AD）外，还包括注射用生物制剂-柯美奇拜单抗注射液-MG-K10（中重度AD）、口服小分子靶向药-CMS-D001（中重度AD）、日常修护-禾零舒缓产品系列，满足AD患者从治疗到日常护理的管理需求。同时，此次增加AD适应症NDA获受理，将进一步强化德镁医药在皮肤治疗领域的战略布局，并与现有处于商业化阶段的创新药益路取（替瑞奇珠单抗注射液）、独家药喜辽妥（多磺酸粘多糖乳膏），以及系列在研创新药和皮肤学级护肤品等在专家网络与市场资源等方面产生协同，提升德镁医药在皮肤健康领域的市场竞争力与品牌影响力。关于磷酸芦可替尼乳膏的更多信息磷酸芦可替尼乳膏（Opzelura(R)）是Incyte开发的选择性JAK1/JAK2抑制剂芦可替尼制成的一种创新型乳膏。在中国，磷酸芦可替尼乳膏获批用于治疗12岁及以上儿童和成人患者伴面部受累的非节段型白癜风。在美国，磷酸芦可替尼乳膏是经美国食品和药物管理局（FDA）批准的首款局部JAK抑制剂，可用于局部治疗12岁及以上患者的非节段型白癜风；及其他外用药控制不佳或不建议使用时，非免疫功能受损的2岁及以上儿童和成人轻中度特应性皮炎的局部短期和非持续性慢性治疗[2]。在欧洲，磷酸芦可替尼乳膏被批准用于治疗成年及12岁及以上青少年面部受累的非节段型白癜风[3]。康哲药业于2022年12月2日，通过德镁医药的附属公司与Incyte就磷酸芦可替尼乳膏订立合作和许可协议（"许可协议"），获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一囯（"区域"）研发、注册及商业化产品的独家许可权利，以及在区域内生产产品的非独家许可权利。德镁医药的附属公司已将磷酸芦可替尼乳膏除中国大陆外的其他区域的相关权利再许可予康哲药业（不包括德镁医药及其附属公司）。Incyte拥有磷酸芦可替尼乳膏全球开发和商业化权利，在美国及欧洲以Opzelura(R)的名称销售。Opzelura(R)和Opzelura(R)标识是Incyte的注册商标。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1.数据来自灼识咨询报告2.FDA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3.EMA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和-医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
Mitsubishi Shipbuilding Ships First Units of Systems for Marine Ammonia-Fueled Engines
Ammonia Fuel Supply System (AFSS) moduleTOKYO, Feb 24, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Shipbuilding Co., Ltd., a part of Mitsubishi Heavy Industries (MHI) Group, has shipped an ammonia fuel supply system (AFSS) and an ammonia gas abatement system (AGAS) for Japan Engine Corporation (J-ENG). Both systems are designed for the first ammonia-fueled marine engine model 7UEC50LSJA-HPSCR manufactured by J-ENG and represent the first units produced by Mitsubishi Shipbuilding. Commissioning work for the systems will begin in due course.The AFSS supplies ammonia fuel to the engine in a stable and safe manner, while the AGAS safely processes surplus ammonia generated during fuel switching from ammonia to conventional fuel oil. Both systems support remote operation and automatic control through an integrated control system, enhancing operational efficiency and safety.The early market introduction of these systems will enable onboard verification combining J-ENG's ammonia fueled marine engine model 7UEC50LSJA-HPSCR, a first mover in next-generation advanced fueled engines, with Mitsubishi Shipbuilding's AFSS and AGAS. This combination is expected to further accelerate decarbonization efforts across the maritime industry.Mitsubishi Shipbuilding will continue strengthening its business structure to meet the growing demand for ammonia-fueled vessels.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
MHI Unveils “DIAVAULT,” a Secure, High Performance Edge Data Center Platform
TOKYO, Feb 24, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) today announced the launch of DIAVAULT, a newly developed industrial grade edge data center(1) brand.DIAVAULT is a digital infrastructure solution that enables on-site data and AI utilization in an on-premises environment (2). It achieves high security and low latency that are difficult to realize in cloud environments. In addition, it is equipped with a stable power supply and cooling systems, enabling long-term stable operation. DIAVAULT will be a key driver accelerating digital transformation in the industrial sector.BackgroundWith the widespread adoption of IoT and AI, industries increasingly require the ability to process large volumes of data in real time. However, cloud-centric processing faces challenges such as latency and data confidentiality risks. Therefore, the importance of edge computing, which enables fast and distributed processing near devices generating vast amounts of data and the users of this data, is increasing.In response to these challenges, MHI is promoting the development of on-premises digital infrastructure. DIAVAULT, centered on a high-security edge data center that simultaneously achieves high on-site information processing and stable operation, flexibly covers customer needs from small-scale to inference data centers (3) of several megawatts. It provides a range of edge solutions such as inference environments in manufacturing sites, research facilities, defense-related fields, and 5G connectivity to meet low latency demands.Key FeaturesRecently, MHI opened a demonstration AI data center on the premises of Yokohama Hardtech Hub (YHH) established at Mitsubishi Heavy Industries Yokohama Works and started validation of various use cases. This data center has the following features:Servers equipped with the next-generation GPU specialized for AI processing are efficiently cooled by two-phase direct chip cooling (4), achieving powerful computing performance and low PUE (5) with excellent cooling performance.The server room is compact, equivalent to two 20-foot containers, but offers a spacious area for the maintenance of large-depth servers and the CDU (6). It is equipped with an uninterruptible power supply with continuous power feed.Proprietary digital integrated air conditioning control technology optimizes air conditioning and heat sources while monitoring server load, delivering energy-saving effects throughout the year.In addition to robust entry/exit security with two-factor authentication, the entire facility is remotely monitored, enabling stable unmanned operation.Future OutlookBuilding on comprehensive engineering capabilities developed in social infrastructure and data center power, cooling, and digital technologies, MHI is advancing solutions with high resilience and high security to support next-generation generative AI and physical AI. With the deployment of DIAVAULT, MHI will promote the widespread adoption and co-creation of more advanced and reliable AI infrastructure through collaboration with domestic and international partners.(1) A small-scale data center installed close to users and devices.(2) A system in which servers are placed at facilities such as company offices, factories, or research institutes to directly manage and process data, rather than using the cloud.(3) A data center optimized for fast and efficient inference after AI models have been "trained." Equipped with AI accelerators specialized for AI processing.(4) A cooling technology that circulates an electrically insulating two-phase refrigerant (liquid and gas) through a cold plate on semiconductor chips (processors) inside the server, removing heat without using water.(5) Power Usage Effectiveness (PUE) is an indicator of how efficiently a data center uses power. The closer to 1.0, the greater the efficiency.(6) CDU (Coolant Distribution Unit) is a device that circulates, distributes, and adjusts the temperature of coolant to efficiently cool IT equipment such as servers.The Edge Data Center "DIAVAULT" in YHHAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
CanSinoBIO’s Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the “NMPA”), pursuant to which, the supplemental application to expand the age range of applicable population of the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “MCV4”, trade name: Menhycia (R)) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved by NMPA.This approval marks an important step forward, underscoring the public health impact of Menhycia (R) while also strengthening its long-term commercial prospects. Under China’s current national immunization schedule, the final pre-school dose of meningococcal vaccination is administered at six years of age. For a long time, multivalent conjugate vaccine options for children over age three have been relatively limited in the domestic market. The newly approved expansion of the eligible age range helps address this gap, providing broader and more appropriate vaccination options for this population.At the same time, the broader eligible population is expected to further unlock Menhycia (R)’s commercialization prospects, and lay a more solid foundation for the product’s promotion and strategic rollout in international markets.Notably, CanSinoBIO issued its Results Forecast For The Year 2025 recently. Forecasting total revenue of RMB 1.04–1.08 billion, a year-on-year increase of 22.88% to 27.61% and net profit attributable to the shareholders of RMB 24.5–29.0 million—marking a return to profitability. The company noted that Menhycia (R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to drive sustained revenue growth under its innovation-led commercialization strategy. This also signifies that the company is now reaping the commercial benefits of its early investments in vaccine innovation.Leveraging its proprietary platform, first-mover advantages, and accelerating global expansion, the age expansion of Menhycia (R) is expected to further strengthen CanSinoBIO’s competitive position while providing new momentum for sustainable growth. As product coverage broadens and international commercialization advances, the company is well-positioned to enter a new phase of long-term growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
康希诺生物曼海欣(R)扩龄正式获批 为公司长期价值开启更广阔发展空间
香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年2月24日，康希诺生物（688185.SH/06185.HK）宣布，公司自主研发的ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）——曼海欣(R)扩大适用人群的补充申请已正式获得国家药品监督管理局批准。此次获批后，曼海欣(R)适用于3月龄至6周岁（83月龄）的婴幼儿及儿童，用于预防由A、C、Y、W135群脑膜炎奈瑟菌引起的流行性脑脊髓膜炎（以下简称"流脑"）。此次曼海欣(R)扩龄获批，具有重要的公共卫生和商业发展意义。一方面，在我国现行免疫规划程序中，6岁是入学前流脑疫苗接种"最后一针"的重要节点，长期以来，国内针对3岁以上儿童的多价流脑结合疫苗选择相对有限。曼海欣(R)此次扩龄获批，为学龄期儿童提供了四价流脑多糖结合疫苗接种选择，有助于填补儿童流脑防控在关键年龄阶段的保护空白，进一步完善我国流脑免疫屏障。另一方面，适用人群范围的扩大，将有助于曼海欣(R)进一步释放产品潜力，提升商业化空间，并为该产品在国际市场的推广与布局奠定更为坚实的基础。值得一提的是，康希诺生物日前已发布2025年度业绩预告，全年营收预计10.4–10.8亿元，同比增长22.88%-27.61%；归母净利润预计2450万–2900万元，将实现扭亏为盈。同时，公告明确指出，"公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗曼海欣(R)收入保持持续增长"。这也意味着康希诺生物已进入创新疫苗商业化收获期。依托独家技术平台、领先优势及加速的国际化布局，曼海欣(R)扩龄不仅巩固了市场竞争力，也为康希诺生物的可持续增长注入新的动力。随着产品覆盖和国际拓展的推进，公司长期价值将开启更广阔的发展空间。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
五一视界x摩尔线程：新一代仿真与GPU完成适配 共筑全栈国产化物理AI底座
香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年新版《道路机动车辆生产企业准入审查要求》中，仿真验证能力被作为强制性关键要素写入准入审查要求，国产仿真平台迎来巨大的市场利好，进一步推动了智驾产业链加速向"自主可控"迈进。在此背景下，五一视界宣布旗下51Sim下一代智驾仿真平台 SimOne 4.0 已于近日成功完成在摩尔线程旗舰级AI训推一体全功能GPU MTT S5000上的系统性适配与深度优化。从大模型感知挖掘、4DGS模型训练到4DGS仿真推理和合成数据生成，双方强强联手，实现了国产算力与端到端智能驾驶仿真体系的完整打通，正式开启了物理AI智驾领域高置信度闭环仿真与合成数据的全栈国产化新篇章,为应对新规下的严苛验证需求提供了坚实的国产底座。算力底座的"跨代式"追赶随着端到端智驾收敛到VLA和世界模型两条路线，基于海量Log数据的高置信度闭环仿真和合成数据已成为提升算法长尾场景处理能力的关键命题。仿真效率的上限，往往取决于基础一硬件的规格。在很长一段时间里，高端GPU市场几乎被海外巨头垄断，但五一视界与摩尔线程的最新合作成果显示，这一格局正在发生微妙的变化。SimOne 4.0已完成与摩尔线程MTT S5000的深度适配。MTT S5000是专为大模型训练、推理及高性能计算而设计的全功能GPU智算卡，基于第四代MUSA架构"平湖"打造。其单卡AI算力（稠密）最高可达1000 TFLOPS，配备80GB显存，显存带宽达到1.6TB/s，卡间互联带宽为784GB/s，完整支持从FP8到FP64的全精度计算。基于SimOne 4.0实现7个周视摄像头4DGS场景重建效果在实测数据中，MTT S5000展现出了足以抗衡甚至部分超越国际主流竞品的硬实力。数据显示，MTT S5000在FP32、FP16及INT8等关键精度上实现了约1.47倍的性能增长，FP64双精度算力领先幅度约1.48倍。更值得关注的是其搭载的MTLink技术，使得卡间带宽提升约30%。MTT S5000凭借FP8提升训推效率、FP64保障计算精准、光线追踪实现高保真渲染，以自主可控的强劲底层算力，为智能驾驶提供安全、高效、可靠的核心国产算力支撑。场景实测：在复杂博弈中验证"真功夫"硬件参数的领先，最终需要在真实的算法场景中落地。在SimOne 4.0的大模型感知挖掘功能中，双方针对Qwen3-VL多模态大模型进行了深度调优。实测结果令人惊喜：无论是在8B模型还是更复杂的30B MoE架构下，MTT S5000在"预填充（Prefill）"阶段的首字响应速度（TTFT）均优于国际主流竞品，优势最高扩大至14%，且在10并发的高压环境下依然保持了稳健的吞吐量。而在更考验训练和推理能力的4DGS（4D高斯泼溅）领域，基于51Sim入选AAAI 2026的LidarPainter技术，国产算力同样经受住了考验。目前测试数据显示，在训练端，MTT S5000展现出比肩国际主流竞品的强劲性能，仅需2.5小时即可完成一个真实Clip场景的高质量重建；在推理端，面对单Clip包含1600万个高斯点的超大模型负载，MTT S5000成功实现了11路摄像头加1路激光雷达的实时闭环仿真，呈现出像素级的高保真效果。这证明了国产显卡在处理复杂光影与动态物体还原时，已经具备了生产力级别的属性,能够胜任准入审查中要求的极端工况与边界条件验证。这种高保真物理场景的重建能力，同样可迁移至具身智能机器人的空间感知与操作训练中。基于LidarPainter 技术生成高真实度新视角图像隐形护城河：构建"芯片+系统"的通用底座如果说高性能GPU的适配是攻克了"最难的骨头"，那么对国产基础软硬件生态的全面覆盖，则是五一视界构筑的一条安全护城河,也是响应国家信创战略、满足敏感行业准入要求的关键。除了图形计算领域，五一视界已悄然完成了对主流国产芯片架构的全线互认。在CPU层面，无论是基于ARM架构的华为鲲鹏、飞腾，还是基于x86架构的海光、兆芯，五一视界旗下的51Aes、51Sim等核心产品均已实现流畅部署。特别是通过华为鲲鹏技术认证并加入"鲲鹏展翅"计划，进一步夯实了其在国产服务器端的运行稳定性。在操作系统层面，为了彻底摆脱对非国产发行版的依赖，五一视界将适配工作下沉至系统内核，先后完成了与麒麟软件（银河麒麟高级服务器操作系统）及统信软件（UOS）的适配认证。这一举措意味着，对于政府、能源等有着严苛信创要求的敏感行业客户而言，他们可以选择从芯片到底层操作系统到上层应用全链路自主可控的数字孪生解决方案,从容应对日益严格的合规性审查,构建起一个不仅服务于智能驾驶，更能广泛赋能于人形机器人等具身智能终端的国产化通用基础设施。中国科技企业"国产自主可控"已经崛起从携手摩尔线程在高端算力上撕开缺口，到打通华为鲲鹏、麒麟等操作系统的生态脉络，再到积极响应新版准入审查要求提供合规的仿真验证能力，五一视界的这一系列动作表明，中国企业的"国产自主可控"正在发生量变和质变，正在缓缓崛起。这不再是简单的参数对标，而是产业生态的战略闭环。SimOne 4.0的表现证明，国产软硬件方案已经迈过了"能用"的门槛，正式进入了高精度、高负载任务的"好用"阶段。随着算法与算力的深度融合，以及政策法规对仿真验证能力的强制加持，一个繁荣的、自主可控的物理AI生态底座正在逐步成型，为中国智能驾驶产业的独立发展保驾护航,也为具身智能机器人等新兴领域的国产化落地铺平了道路。基于SimOne 4.0 的4DGS闭环仿真 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
Galaxy Payroll Group Renews Five-Year Strategic Cooperation Agreement with NIKE China Holding HK Limited (Macau Branch)
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – February 22, Galaxy Payroll Group Limited (NASDAQ: GLXG) (“Galaxy” or the “Company”), a Nasdaq-listed human resources solutions provider, today announced that it has formally renewed a five-year strategic cooperation agreement with NIKE China Holding HK Limited (Macau Branch) (“Nike Macau Branch”).Five-Year Renewal with Comprehensive HR Service CoveragePursuant to the agreement, the renewed cooperation term will commence on December 1, 2025 and continue through November 30, 2030. During this period, Galaxy will continue to provide Nike Macau Branch with a comprehensive suite of human resources outsourcing services, including local payroll processing, attendance and leave management, social security and tax compliance filings, as well as advisory services relating to labor regulations and employment policies.This integrated service model is designed to enable Nike Macau Branch to focus on its core retail and brand operations while enhancing overall organizational efficiency and compliance management.Strategic Renewal Reflects Client Confidence and Enhances Revenue VisibilityThe renewal marks an important milestone in the long-standing relationship between the parties and reflects the continued trust placed in Galaxy’s professional capabilities, compliance standards, and service delivery quality by a leading international brand.The execution of a multi-year agreement is expected to enhance the Company’s revenue visibility and cash flow stability over the next five years, further aligning with its capital markets strategy of building a high-quality, resilient, and sustainable business model. While the agreement provides for long-term cooperation, actual results may vary and remain subject to market and operational conditions.Local Expertise and Scalable Service Infrastructure as Core Competitive AdvantagesSince its establishment in 2013, Galaxy has focused on the Hong Kong and Macau markets while progressively expanding its cross-regional service capabilities. The Company has developed deep expertise in Hong Kong and Macau labor laws, taxation, and social security regulations, forming a strong local compliance foundation.Through a service framework that combines standardized operational processes with customized solutions, Galaxy delivers consistency and scalability across its client base. Its proprietary payroll and attendance management platform enhances operational efficiency while supporting data security and business continuity, serving as a key differentiator in attracting and retaining multinational enterprise clients.Throughout prior phases of cooperation, Galaxy has supported Nike Macau Branch in navigating complex employment and compliance environments. The Company’s solutions have demonstrated reliability in accuracy, responsiveness, and risk control, providing a solid foundation for this long-term renewal.Looking Ahead: From Service Delivery to Value Co-CreationEntering the new cooperation cycle, Galaxy intends to further optimize payroll workflows and intelligent attendance systems within the existing service framework. Through enhanced data integration and periodic management reporting, the Company aims to support the client’s ongoing efforts toward standardized and digitalized human resource management.The parties have also agreed to retain flexibility to expand the scope of services through supplemental agreements, enabling the partnership to evolve in alignment with the client’s business development.The renewal of this five-year strategic agreement not only represents long-term recognition of Galaxy’s professional value, but also underscores the sustainability of its business model. It is expected to further strengthen the Company’s brand presence in the Hong Kong, Macau, and broader Asia-Pacific human resources outsourcing markets, while serving as a replicable benchmark case for multinational retail, sports, and consumer brands.As global enterprises increasingly prioritize compliance efficiency, cost optimization, and organizational resilience, Galaxy continues to leverage its localized expertise, robust service infrastructure, and high-quality client base to build sustainable long-term growth momentum.The Company’s management commented: “We will continue to place service capability at the core of our growth strategy, deepen strategic cooperation with existing high-quality clients, and proactively expand relationships with multinational and regional enterprises that offer long-term value, with the goal of delivering steady and sustainable returns to our shareholders.”Contact informationJune TuoTel: (852) 5983-9260Phone: (86)1392-3804-279Intelligent Joy Limited Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
迦里仕人才与耐吉澳门分公司续签五年战略合作协议 深化长期伙伴关系 夯实高端客户基本盘
香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年2月22日, 纳斯达克上市公司迦里仕人才集团有限公司（Galaxy Payroll Group Limited，NASDAQ: GLXG，以下简称“迦里仕人才”）宣布，已与耐吉中国控股香港有限公司澳门分公司（NIKE China Holding HK Limited (Macau Branch)，以下简称“耐吉澳门分公司”）正式续签为期五年的战略合作协议。合作再延五年，服务范围全面覆盖核心HR职能根据协议，双方合作期限自2025年12月1日起至2030年11月30日止。在此期间，迦里仕人才将继续为耐吉澳门分公司提供涵盖本地薪资发放、考勤与休假管理、社保及税务合规申报，以及劳动法规与用工政策咨询在内的一站式人力资源外包服务。该合作模式有效支持耐吉澳门分公司聚焦其核心零售与品牌运营，提升整体组织效能。战略续约彰显客户高度信任，强化收入稳定性此次续约不仅是双方合作关系迈入新阶段的重要标志，更体现了国际头部品牌对迦里仕人才专业能力、合规水平及长期服务交付质量的高度认可。中长期合约的签署显著增强了公司未来五年收入的可预测性与现金流稳定性，进一步契合其打造高质量、抗周期业务模型的资本市场战略。本地化能力构筑核心壁垒，服务体系持续进化自2013年成立以来，迦里仕人才始终深耕港澳市场，并逐步拓展跨区域服务能力。公司凭借对香港及澳门劳动法、税务及社保政策的深度掌握，建立起扎实的本地合规能力；同时依托标准化流程与定制化方案相结合的服务体系，确保交付的一致性与可扩展性。其自主开发的薪资与考勤管理平台，在提升运营效率的同时有效保障数据安全与业务连续性，成为吸引并维系跨国企业客户的关键优势。在过往合作中，迦里仕人才已多次协助耐吉澳门分公司应对复杂用工环境下的合规挑战，其解决方案在准确性、响应速度及风险控制方面均获得充分验证，为本次长期续约奠定了坚实基础。展望未来：从服务交付迈向价值共创展望新合作周期，迦里仕人才将在现有服务框架基础上，持续优化薪资管理流程与智能考勤系统，并通过数据整合与定期管理报表，助力客户推进人力资源管理的规范化与数字化转型。双方亦约定保留通过补充协议灵活拓展服务范围的机制，确保合作节奏与客户业务发展动态同步。此次五年期战略合作的续签，不仅是对迦里仕人才专业价值的长期肯定，更是对其商业模式可持续性的有力印证。它将进一步巩固公司在港澳及亚太人力资源外包市场的品牌影响力，并为服务更多跨国零售、体育及消费品牌提供可复制的标杆案例。在全球企业日益重视合规效率、成本优化与组织韧性的背景下，迦里仕人才正凭借其深厚的本地化经验、稳健的服务体系与高粘性的优质客户基础，稳步构建长期增长动能。公司管理层表示：“我们将继续以服务能力为核心驱动力，深化与现有优质客户的战略合作，同时积极拓展更多具有长期价值的跨国及区域性企业客户，持续为股东创造稳健、可持续的回报。” Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
沪港新兴产业基石基金在港正式开业
香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2月23日，由上海实业（集团）有限公司（以下简称"上实集团"）与国泰海通证券股份有限公司（以下简称"国泰海通"）联合发起设立的沪港新兴产业基石基金（以下简称"基石基金"）正式启航，进入实质投资阶段。作为全国首支、上海市级市场化运作的证券类港股基石基金，基金目标总规模30亿港元，首期规模10亿港元，将聚焦集成电路、生物医药、人工智能上海三大先导产业，专项支持优质企业赴港上市，深化沪港金融与产业协同。服务上海战略，强化沪港联动上海市政府和上海市国资委指导设立的基石基金，是上海国资服务上海科技创新中心建设、推动重点产业高质量发展的重要举措，将紧密围绕上海前瞻的集成电路、生物医药、人工智能三大先导产业进行战略布局，通过资本市场赋能，加速本地创新企业国际化进程。同时，基金也将充分发挥香港作为国际金融中心的枢纽功能，构建"上海产业+香港资本"的高效联通机制，促进两地金融资源互补与市场互联，打造沪港合作新标杆。创新"双管理人"架构，汇聚两地专业力量基石基金在治理模式上采用创新的"双管理人"架构，由上实集团在港金融投资业务平台上实资本（香港）投资管理有限公司，和国泰海通在港资产管理平台海通国际资产管理有限公司共同担任基金管理人，并由沪港两地协同运营。这一合作架构充分融合了上实集团作为上海在港窗口企业的产业资源与香港本地的运营优势，及国泰海通在全球资本市场和跨境资产管理方面的专业能力，实现"产业+金融"、"上海+香港"的双重优势互补。通过建立完善的投资决策机制与风险控制体系，该架构既确保了基金运作符合国际标准，又保持了与本土产业生态的深度链接，为基金的长期稳健运作奠定了坚实基础。多元化投资策略，专注长期价值基石基金坚持市场化、专业化、国际化运作原则，以产业、金融双重视角，构建覆盖企业全生命周期的投资与赋能体系。通过灵活的多元化策略组合与深度投后服务，系统性支持上海三大先导产业优质企业的业务发展与价值实现。基石基金在重点参与上海三大先导产业优质企业赴港IPO的基石投资之外，还可以参与港股IPO锚定和已上市港股的配售投资，通过无锁定期策略保持基金的流动性，以保证基金投资收益；在市场大幅下跌时，也可通过二级市场方式，增持价值低估的优质公司股票；同时跟进优秀企业再融资及并购重组，助力可持续发展。基石基金将严格遵循"好赛道、好公司、好价格"的遴选标准，重点投向具备核心技术、高成长性和稳健现金流的行业领军企业。强化上海国资在港功能，构建跨境投资新平台基石基金是上实集团和国泰海通强化在港服务功能、完善跨境投资布局的关键举措之一。基石基金不仅进一步完善上海国资基金矩阵，填补国资基金在港股IPO及二级市场策略的空白，服务上海企业赴港上市"最后一公里"融资需求，助力构建"早期投资—成长期融资—公开市场上市"的完整产业投资生态；更通过上实集团和国泰海通的深度合作，强强联手、协作共赢，系统提升跨境合规、资产配置与复杂交易设计能力，进一步增强上海国资服务上海乃至国家战略的综合实力。展望：链接国际资本，赋能创新未来在全球科技创新竞争日益激烈的背景下，沪港新兴产业基石基金的实质启动，标志着上海在对接国际资本市场、服务本土创新方面迈出系统性的一步。在人民币国际化和"惠港五条"等政策红利支持下，基石基金将成为连接内地产业资本与国际金融资源的重要纽带。未来，基石基金将积极把握人民币国际化与金融市场双向开放机遇，持续促进国际资本投资上海核心产业，为上海三大先导产业企业提供全方位的资本服务，助力更多硬科技企业走向世界，为沪港融合与高质量发展贡献力量。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
慧源同创科技不锈钢管道直饮水业务迎政策需求双驱动 拥有全产业链优势 未来将成增长引擎
EQS via SeaPRwire.com / 2026-02-24 / 10:45 UTC+8 （2026年2月24日 – 香港）慧源同创科技集团有限公司（「慧源同创科技」，或连同其附属公司统称「集团」；股份代号：1116.HK）欣然宣布，受益于国家饮用水标准升级与民生工程政策落地，迭加居民健康饮水需求爆发，集团布局的中国不锈钢管道直饮水业务正踏入高增长发展轨道。集团凭借全产业链技术、多场景标杆项目落地及规模化市场覆盖，已成功构筑起行业差异化竞争壁垒，该业务已成为集团未来业绩增长的核心引擎，将随行业发展，持续打开成长空间。 政策需求双轮驱动 行业迈入高增长赛道 中国管道直饮水行业正处于政策与市场的双重红利期，为慧源同创科技业务发展奠定了坚实基础。国家层面，GB5749-2022《生活饮用水卫生标准》于 2023 年正式实施，大幅提升水质安全门槛，为行业高品质发展提供法规与标准支撑；地方层面，南京、济南、深圳、重庆等多地将直饮水工程纳入民生建设重点，出台专项技术规范推动社区、学校、医院等场景系统落地。 市场端，居民健康理念深度普及，对饮用水安全的关注度持续提升，管道直饮水因有效解决二次污染、净水器滤芯更换等行业痛点，更兼具成本及环保多重优势，成为公众多场景饮水的优选方式，市场接受度与渗透率正持续提升。 行业调研报告显示，2017年至2022年中国管道直饮水行业在国民用水中的渗透率以10.7%的速度增长，2022年行业规模达88.7亿元人民币；随着深圳、上海等地全城直饮模式放开，行业需求迎来加速发展期，调研机构预测，2023年至2028年管道直饮水行业年复合增长率（CAGR）将达13.1%，2028 年市场规模有望攀升至185.6亿元[i]，行业高景气为集团不锈钢管道直饮水业务打开了广阔的市场空间。 全产业链核心优势 构筑行业竞争壁垒 慧源同创科技在不锈钢管道直饮水业务上形成了全产业链自主可控 + 智慧化系统集成的核心竞争优势，成为集团区别于行业内其他企业的关键壁垒。集团具备独立控制不锈钢管制作所有环节及流程的生产能力，实现食品级不锈钢管自主生产，从源头保障管网材质安全，彻底杜绝输送过程中的二次污染，同时大幅降低供应链成本，提升产品的市场议价能力。加上，集团提供从净水工艺设计、设备安装到管网铺设、水质监测的全套管道直饮水综合解决方案，搭配智慧化与系统集成技术应用，实现直饮水系统的精细化运营与管理。以广东广播电视台管道直饮水项目计算，集团日供水能力满足超过4,000人饮用需求，采用多级深度净化工艺滤除重金属、细菌病毒等有害物质，搭配全封闭食品级不锈钢回圈管网与24小时线上水质监测设备，实现出水水质即时监控、稳定达标。 多场景标杆项目落地 规模化覆盖超 10 万户家庭 依托核心技术优势，慧源同创科技已在政企单位、高端商业、民生社区、教育机构等多场景打造了标杆项目，实现从一线城市到核心城市群的规模化落地，业务覆盖广州、江门等大湾区核心城市，成为中国不锈钢直饮水领域的标杆企业，累计服务超10万户家庭及数万师生。 随着健康饮水理念的进一步普及、国家与地方直饮水政策的持续落地，以及集团标杆项目的示范效应逐步显现，慧源同创科技不锈钢直饮水业务的市场潜力将持续释放。目前，集团多个标杆项目正加速建设，业务落地节奏持续加快，市场占有率稳步提升。 慧源同创科技集团有限公司行政总裁戴耀权表示：「未来，慧源同创科技将持续加大在管道直饮水智慧化、净水工艺升级等领域的研发投入，深化不锈钢管全产业链布局与系统集成能力，不断提升市场竞争力与品牌影响力。我们预计，不锈钢直饮水业务将成为未来数年业绩增长的核心引擎，为股东带来持续、稳定的投资回报，推动集团整体价值实现跨越式提升。」 - 完 – 关于慧源同创科技集团有限公司 慧源同创科技集团有限公司（股份代号：1116.HK）深耕钢管钢材领域逾30年，是中国不锈钢水管行业标杆品牌，具备「自主研发 - 生产制造」全链条能力。主营业务覆盖不锈钢水管及管件、碳钢板材剪切、管道直饮水解决方案，并延伸至相变蓄能技术领域。 自2023年起，集团加速拓展蓄能业务，聚焦相变蓄能材料（PCM）的研发与生产，可为各行业客户提供个性化蓄冷储热解决方案。公司于 2004 年在香港联交所主板挂牌，官网详情可访问：https://www.hctechgp.com。 [i] 头豹研究院﹕2023年 中国管道直饮水行业概览：饮用水 需求升级，巨量市场潜力有待开发https://pdf.dfcfw.com/pdf/H3_AP202404181630528207_1.pdf 2026-02-24 此财经新闻稿由EQS via SeaPRwire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
Fujitsu expands Uvance for Finance offerings to accelerate DX across financial sector
KAWASAKI, Japan, Feb 24, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced the expansion and reorganization of its Uvance for Finance offerings, initially established in June 2025 to accelerate the digital transformation of financial institutions. These enhanced offerings now cover the entire financial sector, including banking, insurance, securities, credit, and leasing, and are structured into seven new offerings.Fujitsu is promoting Uvance, a business model that addresses societal challenges. Through Uvance for Finance, Fujitsu aims to accelerate the advancement of businesses and services in the financial industry by leveraging data and AI. This will be achieved through three key themes: core solutions, which provide highly reliable account processing and branch solutions; platforms, which utilize data obtained from these core solutions for AI and other applications; and enhanced customer experience and the realization of a smart society, which enrich people's lives. These three themes are organized into seven offerings, which will be expanded sequentially. Fujitsu plans to enhance and further develop Uvance for Finance functionalities by leveraging its AI-Driven Software Development Platform [1], thereby accelerating and strengthening automation through AI. Fujitsu aims to achieve 200 billion yen in sales by fiscal year 2030 from its Uvance financial institution business.Figure 1: Uvance for Finance Offerings StructureUvance for Finance Offerings Structure1. Core Solutions to Power Mission-critical Systems Reliably and FlexiblyThis theme consists of the Reliable Core System, an offering framework that enhances agility and efficiency in core business systems. Fujitsu is expanding its lineup of Fit-to-Standard cloud services to enable agile and efficient core systems compatible with AI.For banks, Fujitsu Core Banking xBank began applying generative AI to feature development in September 2025, progressively transitioning to AI-driven development while ensuring safety and reliability. Additionally, Fujitsu Cloud for Insurance Japan Edition, launched in November 2025 for the insurance industry, and LEASING-1 Neo for the leasing industry are available. Offerings for the credit industry are planned for future release.2. AI/Data Utilization Platform for the Financial IndustryThis category comprises Data Driven Finance, RegTech & Compliance, and Sustainable Finance.Among these, FICO [2] solutions, which contribute to maximizing corporate revenue, minimizing risk, and preventing fraud through accurate credit scoring, data analysis, and decision-making support, are a cross-sectoral platform targeting the entire financial industry, including banking, securities, credit, insurance, and leasing. Among FICO's service offerings, FICO® Customer Communication Services, which optimizes customer communication, launched in July 2025, and the optimization analytics platform FICO Xpress™ Optimization launched in February 2026. The FICO® Platform, which integrates and provides all FICO services, is scheduled to launch within fiscal 2026, enabling Fujitsu to offer the full range of FICO's services.Fujitsu plans to develop agentic AI and other services for the financial industry utilizing its AI platform, Fujitsu Kozuchi and Takane LLM[3], to contribute to customer operational efficiency, automation, and personalization.3. Enhanced Customer Experience and Realization of a Smart SocietyThis category consists of Personalized Experience, Finance Automation, and Embedded Finance offerings.Among these, FinSnaviCloud, a Personalized Experience service that addresses challenges in confirmation operations, has been adopted by 24 financial institutions (as of February 2026). Fujitsu has newly launched a function to automatically generate inheritance relationship diagrams from family registers, supporting financial institutions in resolving manual inheritance operation issues.Furthermore, the Online Medical Certificate Service within Embedded Finance is a newly developed service that connects hospitals and insurance companies to facilitate claim payment procedures. This industry-first service allows insured individuals and beneficiaries to complete claim payments online in a one-stop manner, eliminating the need for paper-based procedures that previously required them to obtain medical certificates from hospitals and submit them to insurance companies. This service is scheduled to launch in May 2026.Additionally, Fujitsu is proceeding with the development of a platform to realize Embedded Finance, which will strongly contribute to the growth of small and medium-sized enterprises and the sustainability of supply chains through timely fund sharing tailored to corporate activities.Figure 2: Uvance for Finance Offerings Lineup [1] AI-Driven Software Development Platform:A development platform that automates the entire software development process, from requirements definition and design to implementation and integration testing, using AI.[2] FICO:Fair Isaac Corporation, Headquarters: Bozeman, Montana, USA, CEO: Will Lansing[3] Takane:A large language model jointly developed by Fujitsu and Cohere Inc.Press Conference MaterialsHeld on February 24, 2026Presentation materials and movie *Coming soonAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
维昇药业（2561.HK）维臻高(R)获批：重长效生长激素王者登场 重构百亿市场的商业天花板
香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年2月2日，维昇药业于上海举办维臻高(R)（注射用隆培生长激素）获批上市投资者交流会。 该产品已于1月26日获得国家药品监督管理局批准上市。公司在会上表示，维臻高(R)被定位为具备里程碑意义的创新产品 - 不仅是首个在欧美获批用于儿童的长效生长激素，也是目前临床研究中唯一被证实在疗效上优于日制剂的长效生长激素产品。在生长激素赛道中，随着多款产品陆续纳入医保、价格体系快速下探，市场竞争格局正在发生变化。维昇药业以临床价值和技术壁垒为核心，打造差异化的高端产品路径。本次交流会由公司管理层系统介绍了产品研发逻辑、临床数据及当前阶段商业化策略的核心思路。本次会议邀请了多位合作伙伴与行业嘉宾出席，包括国妇婴主任医师余文教授、安科生物高级副总裁姚建平先生、副总裁鲍学科先生、上药控股副总经理宋潞潞女士、上海和睦家医院长宁院区执行院长刘晓龙先生等到场支持。同时，公司长期股东代表——碧沃投资合伙人柳丹先生亦出席交流，体现了核心股东对公司商业化路径与长期价值的持续认可。中信证券、东吴证券、天风证券和国海证券等多家大型券商及投资机构亦参与本次会议。一、产品内核：技术壁垒构建差异化护城河1.1 "暂时连接"技术的独特性在生长激素领域，由于技术壁垒高，实现长效化与保持活性分子的天然结构长期被视为"鱼与熊掌不可兼得"，而维臻高(R)的研发上市成功突破这一行业技术壁垒，是全球首款实现"长效化+天然结构"作用机理的长效生长激素。维昇药业首席商务官陈军在会上详细拆解了TransCon技术平台的突破：通过惰性载体（PEG）将天然结构的重组人生长激素暂时包裹和保护起来形成前药，前药在注射至皮下时没有活性，进入血液循环在，将惰性载体与生长激素暂时连接起来的TransCon连接结构在体温与生理pH值下发生自动裂解，7天内以特定的速率逐步释放出与人体自身分泌完全一致的2.2万道尔顿（22kD）、191个氨基酸的天然结构的生长激素。这一"暂时连接"机制与市面上其他长效生长激素的"永久连接"形成本质区别。陈军指出，目前已上市的其他长效生长激素均属于"生长激素类似物"——其活性分子结构已改变，分子量高达6万-9万道尔顿，远远高于天然生长激素的2.2万道尔顿。维臻高(R)进入人体内释放的活性分子与内源性生长激素的分子量、分子结构、组织分布以及药理特性相同，也是首款活性分子是"长效生长激素"而非"生长激素类似物"的长效产品。国妇婴主任医师余文教授从临床角度补充了关键细节：分子量过大的药物难以穿透致密的骨骺板，无法发挥生长激素的直接作用，也就可能直接影响疗效。维臻高(R)以内源性生长激素的"原药形式"发挥作用，是其头对头研究取得优效结果的理论依据和科学基础。1.2 说明书上的"法律证据"余文教授在交流中特别强调，在临床实践中，尤其是一款新药，经国家药监部门审评并写入药品说明书的内容，是判断药品疗效与安全性的核心法定依据，也是临床用药的权威规范标准，它构成了疗效与安全性判断的核心标准,是药品的"身份证"。维臻高(R)本次获批的产品说明书直接显示了其疗效优于每日制剂：境外临床研究结果："主要疗效终点是第52周时年化生长速率（AHV）。本品治疗52周时的AHV非劣效并优效于健豪宁(R)组。此外，本品治疗后的身高SDS较基线的增加幅度高于健豪宁(R)组。从治疗第26周至第52周试验结束时，对于AHV和身高SDS 较基线的变化，本品组都较健豪宁(R)组更显著。"中国临床研究结果："主要疗效终点是第52周AHV。本品治疗52周的AHV为 10.66cm/年，相比诺泽(R)组的AHV 9.75cm/年，统计分析结果显示达到非劣效性以及优效性，即证明了本品治疗的52周AHV优效于诺泽(R)组，与境外3期研究结果一致。此外，本品组治疗时的身高SDS较基线的增加幅度高于诺泽(R)组，也显示了优效性。从治疗第13周至第52周试验结束时， 对于AHV和身高SDS较基线的变化，本品组都较诺泽(R)组更显著。"1.3 安全性设计的双重保障分子安全性：由于维臻高(R)的活性成分与内源性生长激素结构完全一致，避免了未知分子风险；而其他长效生长激素均为"人造分子"，长期安全性存疑（辉瑞、诺和诺德曾尝试PEG永久修饰技术研发长效生长激素，但均因安全性和疗效问题终止研发）。局部安全性：注射部位无活性，避免脂肪萎缩等不良反应。陈军特别解释：其他部分长效产品将"7天剂量一次打入一个注射部位"，注射部位存在高浓度活性成分；维臻高(R)的"包裹"技术使其在皮下无活性，只在该发挥作用时才呈现活性，降低了导致脂肪细胞溶解、皮肤凹陷的可能，这是"另一个安全性优势"。更值得关注的是其长期安全性数据：维臻高(R)全球关键3期研究治疗1年的结果显示，其不良反应发生的种类与频率均与生长激素日制剂相似；而在治疗时间最长达6年的延长期研究中，维臻高(R)也未出现与生长激素日制剂不同的、新的不良反应类型。余教授谈到，生长激素日制剂在生长激素缺乏症患儿中已有超过40年的使用经验，其安全性特已被临床医生熟知并掌握，基于明确的研究数据，维臻高(R)与日制剂一致的安全性表现，显然也为医生的应用提供了更充分的保障。1.4 储存与使用的便利性突破维臻高(R)在不含防腐剂情况下，室温（≤30℃）可储存6个月，在2-8℃条件下可存储5年，是唯一可在室温下长期存放的生长激素。余文教授强调："这是我们当时完全没有想到的效期，并且清楚的写在说明书中。"这一特性对需要携带药物出行、参加夏令营的家庭至关重要。1.5 注射体验的创新设计维臻高(R)配备电子自动注射笔，由Phillips-Medisize公司生产，2022-2023年获欧洲和美国三项工业设计大奖（PDA 药物递送创新奖、PharmaPack 给药与包装创新奖、红点工业设计奖）。其特点包括：- 单按钮开关，药物复溶与注射全自动完成- 隐形针头设计，患儿看不到针，减少心理恐惧- 配合固定剂量双腔预充笔芯，注射前无需调节剂量，同时避免浪费- 每月4支笔芯+6支针头的一体化包装二、市场策略：技术与临床优势下的差异化商业路径2.1 定价逻辑：突出产品差异化，以技术优势形成产品价值优势维昇药业首席商务官陈军表示：维臻高(R)的年治疗费将会于产品上市时最终确定，但一定会显著高于其他长效生长激素纳入医保后的价格。但这一定价并非简单的"高端溢价"，而是基于三重锚定：- 价值锚定：产品具备"天然结构+优效+室温保存"三重独特属性，维臻高(R)作为长效生长激素迭代产品，产品的独特优势赋予了其核心定价权，将填补高端市场的真空。- 国际锚定：该产品在欧美获批上市，美国年治疗费用50-60万元，维臻高(R)以其"技术优势+临床优势+欧美品质"为背书，将临床需求和价值锚点与国际接轨。- 长期健康价值锚定：生长激素治疗具有明确的时间窗口和长期获益特征。其价值并不取决于单一年度的费用比较，而在于对终身身高结局、心理健康与社会功能的长期改善。从全周期视角衡量，该治疗所带来的健康收益与成本投入之间具有清晰、可解释的价值逻辑。这一策略的风险在于支付能力，但维昇药业的判断是：生长激素市场90%以上为自费，80%以上销售发生在私立医院。2.2 渠道布局：合纵连横的"作战地图"维昇药业作为初创企业，选择了"轻资产、重合作"的扩张路径：- 推广端：与安科生物强强联手，其高级副总裁姚建平表示，公司在生长激素领域深耕27年，以学术触达95%的生长激素KOL专家。此次与维昇药业的合作，"27年经验+划时代产品"将形成前所未有的商业化布局。双方将按地域区隔运营，维昇药业自营沿海核心市场，安科生物负责其余广阔区域，实现市场的全面覆盖。- 流通端：上药控股作为进口分销平台，依托其成熟的供应链体系，提供从通关到终端的全程服务。上药控股副总经理宋潞潞指出，维臻高(R)是其经销的大分子生物药中，唯一不含防腐剂且可常温保存6个月的产品，"这两个优势在对药品商业化成功，特别是儿童用药的商业化成功方面，至关重要"。- 诊疗端：与和睦家、小苹果、卓正等高端私立医院建立深度合作，构建"筛查-诊疗-管理"的全流程闭环。上海和睦家医院长宁院区执行院长刘晓龙表示，其患者群体对"技术领先、长期安全"的产品需求明确，维臻高(R)的核心优势与该群体需求高度匹配，具备良好的临床土壤。- 流量端：患者及家庭在疾病认知与治疗决策过程中，主要通过内容社区、AI 搜索工具及合规的互联网医疗平台获取相关科普信息，逐步形成以专业性、可及性和合规性为核心的患者信息入口，让优质医疗信息精准触达目标人群。三、团队建设：用近乎苛刻的标准筛选最强执行者维昇药业销售与商业运营副总裁潘海风详细介绍了团队建设的"高强度、严标准"体系：- 招聘标准：一线商业化团队中，约20%具备硕士学历，80%为医药相关本科背景；近三分之一来自其他公司的地区经理级别，整体商业化人员结构和行业经验显著高于行业平均水平。- 考核机制：全员"日考+周考+月考"，内容涵盖产品知识、竞品知识、临床医学、疾病知识；每日考试须达90分以上，集训落地考不合格者原机遣返，以严苛的考核标准保障团队的专业能力，确保用人标准与产品价值相一致。- 提前布局：公司提前规划、前置投入，产品上市前6个月商业化团队已90%到岗，为产品上市后的快速市场推进做好了充分准备，体现出公司对商业化执行的前置投入与系统规划。四、其他Q&A环节：问题一：在目前的定价水平下，维臻高(R)的利润率表现如何？未来随着地产化推进，盈利空间如何展望？ 回答： 公司坚持"先上市、先可及"的策略，进口阶段的毛利率足够产品上市早期的推广。随着两年多后实现地产化生产，即便在当前价格水平大幅下降的情况下，毛利率仍有望达到80%以上。从进口到地产化的路径清晰，随着市场规模的持续放量，盈利能力将随规模放量持续改善。问题二：维臻高(R)在公立医院与民营医院中的销售场景如何落地？在部分长效生长激素已进入国谈的背景下，公司如何发挥差异化优势？ 回答： 公司将覆盖三类渠道：公立医院院内、公立医院处方外配及民营医院。受国谈因素影响，公立院内并非未来主战场，核心增长将来自处方外配及民营医疗体系。同时，国家层面已明确提出要有序推进医师多机构执业，鼓励医师依法开展多点执业，医生在公立医院与民营医疗机构之间的执业流动性持续提升。这一趋势为创新、差异化产品在院外及民营场景中的推广和规范使用创造了有利条件。公司将基于这一制度环境，在所有合规场景中积极布局。问题三：除维臻高(R)外，公司其他管线在未来几年的上市节奏及协同贡献如何？ 回答： 公司在内分泌领域已布局多条管线，其中针对甲状旁腺功能减退的帕罗培特立帕肽已分别于2024年年初和年底在欧盟跟美国获批；第三个品种那韦培肽这个月底迎来其 PDUFA 日期，后续产品在中国的上市节奏有望加快。多产品协同放量后，公司整体规模有望持续跃升，长期目标是打造内分泌与代谢领域具备国际竞争力的百亿级创新药企。问题四：已使用短效生长激素的患者，是否可以无缝切换至维臻高(R)？是否有相关临床证据支持？ 回答： 国际3期试验有一个关于日制剂转换为隆培生长激素的研究。研究显示，对于平均使用日制剂已有1.14年、平均剂量为0.29 mg/kg/周的患者，转为隆培生长激素0.24mg/kg/周后，仍然保持了非常良好的追赶生长的趋势。这一研究结果证明了由日制剂转为隆培促生长素每周一次治疗仍可保持非常良好的生长趋势和疗效。问题五：维臻高(R)在长期使用方面的疗效和安全性表现如何？ 回答： 在国际3期试验的延长期实验中，患者平均治疗4.3年、最长达6年，期间患者身高持续改善，部分患者最终身高SDS甚至超过父母平均身高SDS，充分体现了产品在长期治疗中的有效性、安全性及稳定性。问题六：公司目前商业化团队建设情况如何？与安科生物的合作如何推进？ 回答： 公司首年商业化团队已基本到位，团队人员以业内资深骨干为主，强调高专业度、强培训与严格考核。区域运营上，维昇负责沿海一线重点城市，安科覆盖其他区域，双方执行统一学术与培训标准，形成"强强联合"的销售体系，共同推进产品的市场落地。五、长期展望：从单一产品到平台价值维昇药业执行董事兼首席执行官卢安邦在交流结束的致辞中描绘了公司长期发展的蓝图：维臻高(R)的获批意味着TransCon技术平台继FDA和EMA后获NMPA认可，为后续产品铺平道路。在研的帕罗培特立帕肽（甲状旁腺功能减退症）2024年美欧获批后首年销售近40亿人民币，那韦培肽（软骨发育不全）针对中国1万患儿的治疗刚需。"2026-2028是公司"十年磨一剑"的决战期，"卢安邦表示，"我们要验证从临床、注册、准入到商业化的端到端能力，最终成为内分泌代谢领域的百亿级领军企业。"本文基于2026年2月2日维昇药业投资者交流会纪要整理，内容仅供信息参考，不构成投资建议。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
MHI Thermal Systems Establishes Local Subsidiary in India and Starts Operations
TOKYO, Feb 24, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Thermal Systems, Ltd. (MHI Thermal Systems), a part of Mitsubishi Heavy Industries (MHI) Group, has established a local subsidiary in India as a production base for air conditioners. Mitsubishi Heavy Industries-IAPL Air Conditioners Private Limited, a joint venture with IAPL Group Private Limited (IAPL), MHI Thermal Systems' distribution partner in India, started operations on January 22.The Indian air-conditioning market is forecast to maintain robust demand growth due to increasing penetration rates and the characteristics of the regional climate. MHI Thermal Systems has been steadily expanding its business in India by importing and selling air conditioners manufactured in Thailand, working in cooperation with IAPL to establish a nationwide sales and service network.Establishing a local production base in collaboration with its long-time business partner IAPL will allow MHI Thermal Systems to further strengthen its sales network in the fast-growing Indian market, provide regular after-sales service, expand supply to meet increased demand, and bolster its production system and supply chain. In addition, the establishment of a local supply chain serving local markets will further accelerate business expansion in India.In its 2021 Medium-Term Business Plan released in October 2020, MHI Group announced MISSION NET ZERO, its declaration to achieve carbon neutrality by 2040. Realizing a carbon-neutral world is an important global issue, and as a leader with a particular strength in decarbonization technologies, MHI Thermal Systems will progressively introduce products with low-GWP (Global Warming Potential) refrigerants and high energy-saving performance, and pursue business aimed at achieving MISSION NET ZERO.Overview of the New CompanyCompany NameMitsubishi Heavy Industries-IAPL Air Conditioners Private LimitedRepresentativeHideki YamahiraBusiness DescriptionManufacture and sale of air conditionersDate of EstablishmentJanuary 22, 2026LocationHaryana, Republic of IndiaAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
Hong Kong Tech Delegation Heading for Market Expansion at Mobile World Congress 2026
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – Hong Kong Trade Development Council (HKTDC), in collaboration with Hong Kong Science and Technology Parks Corporation (HKSTP), will lead a delegation of 21 Hong Kong tech companies and institutions to showcase at Mobile World Congress (MWC) 2026—the world’s premier connectivity event, and debut at 4 Years From Now (4YFN) 2026—a global stage for start-ups, taking place concurrently 2-5 March in Barcelona, Spain. Building on the momentum from MWC 2025 — the Delegation will be featuring solutions beyond the Connectivity category, covering focus areas across Devices and Systems, Digital Transformation and support from Ecosystem Partners. The Pavilion duet ought to give a more comprehensive picture of Hong Kong’s innovation and technology (I&T) capabilities in engaging global telecom leaders, enterprise decision-makers, industry partners, and investors, bridging cutting-edge research and development (R&D) into real-world applications and propelling Hong Kong’s I&T sector onto the international stage.Iris Wong, Director, Merchandise Trade and Innovation / Director, External Relations, HKTDC, said, “The Hong Kong Tech Pavilion is an ideal platform for Hong Kong tech enterprises to present their latest R&D achievements at major international tech gatherings, support their journey to explore overseas markets, while highlighting Hong Kong’s strengths as an international innovation and technology hub.”Derek Chim, Head of Startup Ecosystem and Development, HKSTP said, “MWC is a global bellwether for communications technology and tech companies at any stage, to connect with the industry and investors, to have a solid ground that validate solutions, catalyse pilot projects, accelerate commercialisation, and scale internationally.”A series of dialogues and exchanges, spanning from networking reception and themed talks to pitching sessions, will take place throughout the events at the Pavilion to facilitate partnerships and investment opportunities for innovative solutions that are market-ready with high potential for market expansion, in particular, Asmote and Cresento under “Connectivity” make stellar examples of the notion:5G & 6G for Communication, Sensing, and AI computing – Shannon & Turing, (Asmote), located at MWC, specialises in mmWave technology for Integrated Sensing and Communication (ISAC) technology—drone communications and control—rising to the occasion as the city advances its low-altitude economy initiatives, while winning favors for its efficiency in managing industrial scenarios such as smart ports and dark factories. The company previously secured the world’s first 26GHz mmWave 5G commercial communications project, demonstrating its leadership in industrial-grade applications.Smart Performance Insights for Sport – Cresento, located at 4YFN, focused on developing an AI-powered shin guard to deliver real-time insights—performance analytics, team leaderboards, and more—with a design that incorporates into gears that athletes already wear and creates minimal friction for, in particular, football players to adapt, will be moving from prototypes to pilot collaborations with European football clubs, academies and sport tech platforms and distributors.HKTDC continues to join hands with HKSTP to support Hong Kong tech enterprises to “go global” by jointly organising the Hong Kong Tech Pavilion to build bridges linking tech companies with the world. This expedites the industry’s progress in internationalisation to meet the growing demand for I&T globally. This will attract talents, facilitate forward-looking investments and explore opportunities globally, realising the mission of entrepreneurs to reach out to the world and further consolidate Hong Kong’s position as an international I&T hub.Mobile World Congress Barcelona (MWC) & 4 Years From Now (4YFN)Date: 2-5 March 2026Venue: Fira Gran Via, Av. Joan Carles I, 64, 08908 L'Hospitalet de Llobregat, Barcelona, SpainHong Kong Tech Pavilion:MWC – Booth 6E44 at Hall 64YFN – Booth 8.1B31 at Hall 8.1Please visit https://bit.ly/MWC2026HKTech for more information on Hong Kong Tech Pavilion and the exhibitors.Appendix: Full list of 21 tech entities showcasing at Hong Kong Tech Pavilion during MWC and 4YFN 2026 (in alphabetical order)No.Name of Tech Company / InstitutionCategoryMWC 2026 – Booth 6E44 at Hall 61Entoptica LimitedDevices & Systems2eSIXConnectivity3Faraconix Technologies Co., Ltd.Connectivity4FreightAmigo Services LimitedDigital Transformation5Glassdio Scientific Company LimitedConnectivity6Harvest Elite International LimitedDigital Transformation7HongKong Umedia LimitedDevices & Systems8iASPEC Services LimitedDigital Transformation9InvestHKEcosystem Partners10Robocore Technology LimitedDevices & Systems11Shannon & Turing Technology LimitedConnectivity12The Hong Kong Polytechnic UniversityEcosystem Partners13Xeroptix TechnologyDevices & Systems4YFN 2026 – Booth 8.1B31 at Hall 8.114AIGM LimitedDigital Transformation15BWSea Technology (HK) Co., LimitedDigital Transformation16Cresento LimitedDevices & Systems17GoGoChart Technology LimitedDigital Transformation18HairCoSys LimitedDevices & Systems19KNQ Technology LimitedDigital Transformation20Solos Technology LimitedDevices & Systems21Vista Innotech LimitedDevices & SystemsAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 16,000 research professionals and around 2,600 technology companies from 24 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.More information about HKSTP is available at www.hkstp.org.Media Contact: Hong Kong Science and Technology Parks CorporationHong Kong Trade Development CouncilAngela LauTel: +852 6535 7611Email: angela.lau@hkstp.orgWinnie KanTel: +852 2584 4055Email: winnie.wy.kan@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com